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Abstract
Background: The formation of new lymphatic vessels provides an additional route for tumour cells to metastasize.
Therefore, inhibiting lymphangiogenesis represents an interesting target in cancer therapy. First evidence suggests
that histone deacetylase inhibitors (HDACi) may mediate part of their antitumor effects by interfering with
lymphangiogenesis. However, the underlying mechanisms of HDACi induced anti-lymphangiogenic properties are
not fully investigated so far and in part remain unknown.
Methods: Human lymphatic endothelial cells (LEC) were cultured in vitro and treated with or without HDACi. Effects
of HDACi on proliferation and cell cycle progress were analysed by BrdU assay and flow cytometry. Apoptosis
was measured by quantifying mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. In vitro
lymphangiogenesis was investigated using the Matrigel short term lymphangiogenesis assay. The effects of TSA on
cell cycle regulatory proteins and apoptosis-related proteins were examined by western blotting, immunofluorescence
staining and semi-quantitative RT-PCR. Protein- and mRNA half-life of p21 were analysed by western blotting and
quantitative RT-PCR. The activity of the p21 promoter was determined using a dual luciferase assay and DNA-binding
activity of Sp1/3 was investigated using EMSA. Furthermore, siRNA assays were performed to analyse the role of p21
and p53 on TSA-mediated anti-lymphangiogenic effects.
Results: We found that HDACi inhibited cell proliferation and that the pan-HDACi TSA induced G0/G1 arrest in LEC.
Cell cycle arrest was accompanied by up-regulation of p21, p27 and p53. Additionally, we observed that p21 protein
accumulated in cellular nuclei after treatment with TSA. Moreover, we found that p21 mRNA was significantly up-
regulated by TSA, while the protein and mRNA half-life remained largely unaffected. The promoter activity of p21 was
enhanced by TSA indicating a transcriptional mechanism. Subsequent EMSA analyses showed increased constitutive
Sp1/3-dependent DNA binding in response to HDACi. We demonstrated that p53 was not required for TSA induced
p21 expression and growth inhibition of LECs. Interestingly, siRNA-mediated p21 depletion almost completely reversed
the anti-proliferative effects of TSA in LEC. In addition, TSA induced apoptosis by cytochrome c release contributed to
activating caspases-9, −7 and −3 and downregulating the anti-apoptotic proteins cIAP-1 and −2.
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Conclusions: In conclusion, we demonstrate that TSA - a pan-HDACi - has distinct anti-lymphangiogenic effects in
primary human lymphatic endothelial cells by activating intrinsic apoptotic pathway and cell cycle arrest via p21-
dependent pathways.
Keywords: Histon deacetylase inhibitors (HDACi), Lymphangiogenesis, G0/G1 cell cycle arrest, p21, intrinsic apoptotic
pathway
Background
Histon deacetylases (HDACs) are highly conserved en-
zymes involved in the control of acetylation of histones
and nonhistone proteins by which mammalian cells
regulate transcriptional activity. The epigenetic control
of gene expression results from the balance between
the opposing activities of histone acetyltransferases
(HATs) and HDACs. Histone hyperacetylation is associ-
ated with increased transcriptional activity, whereas de-
creased levels of acetylation are associated with the
repression of gene expression. Eighteen human HDACs
have been identified so far and are subdivided into four
classes. HDAC 1, 2, 3 and 8 belong to class I, HDAC 4,
5, 6, 7, 9 and 10 belong to class II, class III consists of
sirtuins (SIRT1-7) and to class IV belongs to HDAC 11
[1, 2]. Increased HDAC activity is associated with the
initiation and progression of various types of cancer by
dysregulation of genes which are involved in differenti-
ation, cell cycle control, apoptosis and DNA replication.
Aberrant expression and activity of HDACs was found
in various cancer entities including melanoma, breast
cancer, gastric cancer, prostate cancer and acute mye-
loid leukemia [3, 4]. A dysregulation of the HDAC/
HAT-system leads to the induction of tumourangiogen-
esis. Several natural and synthetic HDACi have been
identified so far and have been shown to inhibit the en-
zymatic activity of HDACs. HDACi exhibits anti-cancer
effects by inducing differentiation, growth arrest or
apoptosis in a number of tumour cell lines in vitro.
HDACi have to been found to inhibit anti-apoptotic
genes (e.g. bcl-XL and bcl-2) and induce pro-apototic
genes (e.g. Bax, Bim, CD95 and CD95L) in several
tumour cell lines including glioblastoma, lymphoma,
prostate cancer and non-small-cell lung carcinoma. In
addition, HDACi induce genes which are involved in
the control of differentiation, proliferation and the cell
cycle (e.g. p21WAF1/KIP1, p27KIP1, p53, cyclin A, B and D)
[5]. Furthermore, HDACi have been shown to reduce
angiogenesis by modulating angiogenesis-related genes,
such as hypoxia inducible factor-1α (HIF-1α), vascular
endothelial growth factor (VEGF) and endothelial nitric
oxide synthase (eNOS) [6]. So far, four compounds exhi-
biting activity against HDACs – vorinostat (suberoylani-
lide hydroxamic acid; SAHA), romidepsin (FK228;
depsipeptide), belinostat (PXD-101) and panobinostat
(LBH-589) – have been approved by the Food and Drug
Administration for the treatment of relapsed cutaneous T-
cell lymphoma, peripheral T-cell lymphoma and multiple
myeloma [7]. Several clinical trials of HDACi are under-
way [8]. Lymphangiogenesis, like angiogenesis, is a com-
plex process of formation of new lymphatic vessels from
pre-existing lymphatic vessels. In the adult organism,
lymphangiogenesis is under physiological conditions re-
stricted to the endometrium during pregnancy, wound
healing or regeneration, tissue repair and inflammation
[9]. Recent studies have identified lymphangiogenesis as
an important pathophysiological factor of tumour pro-
gression and prognosis in cancer patients. It has been
found that increased tumoural lymphatic vessel density is
associated with poor prognosis, a disease free condition
and overall survival in patients with melanoma, breast
cancer and colorectal cancer [10]. Therefore, inhibiting
lymphangiogenesis represents an interesting target in can-
cer therapy. First evidence in an artificial immortalized
lymphatic endothelial cell model has demonstrated anti-
lymphangiogenic activities of HDACi [11]. Taking into
account that HDACi are promising compounds with anti-
tumorigenic activities, we addressed this issue and tried to
elucidate the underlying molecular mechanisms of anti-
lymphangiogenic properties by HDACi in primary human




Human dermal lymphatic endothelial cells were pur-
chased from AngioBio (Del Mar, CA, USA). The cells
were isolated from the dermis of juvenile foreskin from
different donors. The cells were cultured until the eight
passage at 37°C and 5% CO2 in an endothelial cell
growth medium supplemented with 10% human serum
(Lonza, Basel, Switzerland). All experiments have been
replicated in different cells from different donors.
Ethics statement
Primary human material was not used in this study. All
work presented has been performed in established, com-
mercially available primary cells.
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Chemicals
Recombinant VEGF-A and VEGF-C were purchased
from ReliaTech (Wolfenbüttel, Germany). Sodium
Butyrate (NaB), Trichostatin A (TSA) and Valproic Acid
(VPA) were obtained from Merck Millipore (Billerica,
MA, USA).
Fluorescence-activated cell sorting analysis
Cells were incubated with 400 nM TSA and Ethanol as a
control for 24 h after blocking the S-phase of the cell-
cycle by treatment with a serum depleted-medium for 24
h. The cells were fixed in ice-cold 70% ethanol. Cells were
incubated in PBS containing 40 μg/mL RNase A for 30
min at 37°C and resuspended in PBS containing 50 μg/mL
propidium iodide. Analysis of the cell cycle was assessed
by a BD FACScan Cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA).
Cell proliferation assay, cell viability assay and
cytotoxicity assay
The effects of NaB, TSA and VPA on cell proliferation
were measured by quantifying BrdU (Bromodeoxyuri-
dine) via a cell proliferation immunoassay from Roche
Diagnostics (Mannheim, Germany). Twenty-four hours
after seeding (1.5×104/well, 96-well plates) cells were
incubated with 10 μM BrdU and NaB, TSA and VPA at
the indicated concentrations for 24 h. The incorpor-
ation of BrdU into proliferating cells was detected by
using a peroxidase-conjugated antibody which reacts
with the thymidine analogue BrdU and with BrdU in-
corporated into newly synthesized DNA. Bound anti-
BrdU-peroxidase conjugated antibody was detected by
a substrate reaction, and then quantified colorimetri-
cally at 370 nm with a reference wavelength of 492 nm
by an ELISA plate reader (ELISA-Reader ASYS Expert
96, Deelux Labortechnik, Gödenstorf, Germany). Cell
viability was determined in LECs using alamar blue
assay (Bio-Rad, Puchheim, Germany) which quantifies
the metabolic conversion of resazurin to a highly fluor-
escent resorufin by viable cells. Twenty-four hours
after seeding (1x105/well, 96-well plates) cells were in-
cubated with NaB, TSA and VPA at the indicated con-
centrations for 24 h. Alamar blue dye was added and
the plates were incubated at 37°C for 6 h. The color
change was measured fluorometrically at 530 nm
excitation and 620 nm emission by using CytoFluor
4000 fluorometer (Perspective Biosystems, Framing-
ham, MA, USA). The cytotoxic potential of TSA was
determined using a lactate dehydrogenase-based
cytotoxicity detection kit from Roche (Mannheim,
Germany). Twenty-four hours after seeding, the cells
were incubated with TSA for 24 h at the indicated
concentrations.
Short term lymphangiogenesis assay
Growth factor reduced Matrigel™ (BD Discovery Labware,
Bedford, MA, USA) was placed into the lower chambers of
μ-slide angiogenesis wells (IBIDI, Planegg/Martinsried,
Germany) and hardened for 30 min at 37°C. Then, 1.5×104
LECs/wells were seeded on the Matrigel and were either
left untreated (solvent only, Ethanol) or incubated with
TSA (at 400 nM for 6 h). Images were taken on the Biozero
BZ-8000K microscope (Keyence Deutschland GmbH,
Frankfurt am Main, Germany). Image acquisition was per-
formed using BZ analyser software (Keyence Deutschland
GmbH, Frankfurt am Main, Germany).
Apoptosis assay
The effect of TSA on apoptosis was analysed using a Cell
Death Detection ELISA PLUS-Kit from Roche Diagnostics.
This assay detects DNA fragmentation that is characteristic
of apoptotic cell death by quantifying mono-and oligonu-
cleosomes in the cytoplasmatic fraction of cell lysates. The
assay was carried out according to the manufacturers’ in-
structions. Briefly, synchronized cells were seeded in 96-
well plates (1.5×104 per well) and were exposed to 400 nM
TSA for 24 h as indicated. Cell lysates were placed into a
streptavidin-coated microtiter plate followed by the
addition of anti-histone-biotin and anti-DNAperoxidase.
The quantification of the amount of nucleosomes retained




LECs were plated in cell culture dishes (5×106 cells/60
cm2) and treated the next day with TSA as aforemen-
tioned. After 24 h, cytoplasmic extracts were obtained
by digitonin permeabilization. Briefly, cells were trypsi-
nized (0.125% trypsin/0.1% EDTA) for 5 min and centri-
fuged at 259 g for 10 min, and the pellet was
resuspended in 250 μl PBS. Permeabilization of the
membranes was obtained by adding 250 μl digitonin/su-
crose (80 mg/ml, Fluka, Buchs, Switzerland) for 30 s.
Then, samples were centrifuged for 1 min at 14000 g
[12], and supernatants with equal amounts of protein
(protein determination by DC protein assay; BioRad,
Munich, Germany) were used in a commercial cyto-
chrome c immunoassay kit (R&D Systems, Wiesbaden,
Germany). The assay was performed according to the
manufacturer’s manual. Optical density (450 nm) was
measured using an ELISA reader (ELISA-Reader ASYS
Expert 96, Deelux Labortechnik, Gödenstorf, Germany).
Western blot analysis
Protein extracts were prepared as described previously
[13]. Following SDS-PAGE and electroblotting, mem-
branes were incubated with the following primary
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antibodies: anti-p21 (#2947, Cell Signaling, Danvers,
MA, USA), anti-p27 (#3686, Cell Signaling, Danvers,
MA, USA), anti-p53 (#9282, Cell Signaling, Danvers,
MA, USA), anti-cleaved caspase 3 (#9661, Cell Signaling,
Danvers, MA, USA), anti-cleaved caspase 7 (#9491, Cell
Signaling, Danvers, MA, USA), anti-cleaved caspase 9
(#9501, Cell Signaling, Danvers, MA, USA), anti-cIAP-1
(#4952, Cell Signaling, Danvers, MA, USA), anti-cIAP-2
(#3130, Cell Signaling, Danvers, MA, USA), anti-tubulin
(#3873, Cell Signaling, Danvers, MA, USA), anti-cyclin A
(sc-271645, Santa Cruz, CA, USA), anti-cyclin D1 (sc-718,
Santa Cruz, CA, USA), anti-CDK4 (sc-70831, Santa Cruz,
CA, USA) and anti-CDK6 (sc-177, Santa Cruz, CA, USA).
Primary antibody application was followed by incubation
with horseradish peroxidase-conjugated secondary anti-
bodies (anti-mouse and anti-rabbit IgG, Amersham,
Uppsala, Sweden; anti-goat, Dako, Glostrup, Denmark).
Blots were developed using an enhanced chemilumines-
cence detection system (Amersham) according to the
manufacturer’s instructions.
Immunolocalization of p21
To analyse the intracellular distribution of p21 in LECs,
cells were seeded on glass coverslips in 24-well plates. The
cells were grown in endothelial cell growth medium sup-
plemented with 10% human serum for 24 h, fixed with
methanol at −20°C and permeabilized with 0,1% TritonX-
100 for 5 min at room temperature. Permeabilized cells
were rinsed three times with PBS and incubated in block-
ing solution (1% bovine serum albumin/PBS) for 30 min
at room temperature to remove nonspecific binding of the
antibody. p21 was detected using a rabbit monoclonal
anti-p21 antibody (#2947, Cell Signaling, Danvers, MA,
USA) and an Alexa Fluor 546 goat anti-rabbit IgG second-
ary antibody. The slides were mounted in Aqua-Poly/
Mount (Polysciences, Inc., Warrington, PA, USA) and
viewed with fluorescence microscopy. Cells were counter-
stained for nuclei with Hoechst staining.
Small interfering RNA
All small interfering RNA (siRNA) reagents including
transfection reagents were obtained from Santa Cruz
biotechnology (Santa Cruz, CA, USA). Cells were trans-
fected with non-target siRNA (siRNA-A), used as negative
control, p21 siRNA and p53 siRNA. The experiments
were carried out following the manufacturer’s standard
procedures. Total protein was extracted, and Western blot
analysis was performed.
RNA extraction and reverse transcription–PCR
Reverse transcription–PCR (RT-PCR) analyses were per-
formed on total RNA (150 ng) extracted from subconflu-
ent cell cultures. Total cellular mRNA was isolated by
the RNeasy Mini Procedure (Qiagen, Hilden, Germany)
after DNase digestion. RT-PCR analyses for p21, p27,
p53 and β-Actin were performed with the One StepRT-
PCR Kit (Qiagen, Hilden, Germany). PCR products were
resolved by 1–2% agarosegel electrophoresis, and eth-
idium bromide-stained bands were visualized using an
ultraviolet transilluminator.
Real time PCR analysis
Total cellular RNA was isolated by the RNeasy Mini
Procedure (Qiagen, Hilden, Germany) after DNase di-
gestion. 750 ng of RNA was used for first strand cDNA
synthesis using QuantiTect RT-Kit (Qiagen, Hilden,
Germany). Real time PCR reactions were performed with
the SYBRgreen dye technique on a Light Cycler system
(Roche Diagnostics, Mannheim, Germany).
Transient transfection and analysis of reporter gene
expression
Human lymphatic endothelial cells (0.8×105/well, 12-well
plates) were transfected with 1 μg of an appropriate firefly
luciferase construct and 0.5 μg of phRG-TK vector
(Promega, Mannheim, Germany) using the SuperFect
transfection reagent (Qiagen, Hilden, Germany). Human
p21 reporter gene constructs were described elsewhere
[14]. Twenty-four hours after transfection, control trans-
fectants were left untreated and test transfectants were ex-
posed to 400 nM TSA for 24 h. The activities of luciferases
were measured utilizing the Dual-Luciferase Reporter
Assay System from Promega (Mannheim, Germany).
Preparation of nuclear extracts and gel mobility-shift
analysis
Human lymphatic endothelial cells were untreated (solvent
only, Ethanol) or were incubated with 400 nM TSA for 60
min. Nuclear proteins were extracted as described previ-
ously [15]. The DNA-binding reactions were performed by
using nuclear extracts (3.5 μg) and biotin-labeled DNA
probes with or without a competitive cold DNA probe, a
Sp1 and Sp3 antibody (Santa Cruz, CA, USA). Protein-
DNA complexes were detected by streptavidin-HPR and
ECL (Signosis, Santa Clara, CA, USA).
Statistical analysis
Data are expressed as mean ± SE from ≥3 independent
experiments. Statistical analysis was performed by a
Student’s t-test.
Results
Effects of HDACi on cell proliferation, cell viability and
in vitro lymphangiogenesis in human lymphatic endothelial
cells (LEC)
We investigated the impact of HDACi on lymphangio-
genesis in primary human lymphatic endothelial cells
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in vitro. First, we tested the effects of different HDACi
(NaB, TSA and VPA) on cell proliferation and cytotox-
icity using human primary lymphatic endothelial cells
(LECs). In our analyses we found that HDACi inhibited
cell proliferation and viability in a concentration-
dependent manner, as determined by the BrdU and ala-
mar blue assay. Interestingly, these effects could not be
abrogated by the addition of the pro-lymphangiogenic
growth factors VEGF-C and -A, indicating that HDACi
could influence angiogenic signaling pathways (Fig. 1a,
b). To determine the cytotoxic effects of TSA, a potent
pan-HDACi, we performed lactate dehydrogenase assays
and found no cytotoxic effects (Fig. 1c). Furthermore,
we could demonstrate, by using a matrigel assay, that
TSA inhibited capillary-like structure formation (Fig. 1d).
These data suggest that HDACi have distinct anti-
lymphangiogenic effects by affecting lymphatic endothe-
lial cell functions.
TSA induces G0/G1 cell cycle arrest in LECs
To investigate the major underlying mechanisms of
HDACi-induced growth inhibition of LECs, we next
analysed the cell cycle distribution using flow cytome-
try. We found that the percentage of cells in the G0/G1
phase was significantly increased upon TSA treatment
for 24 h (Ctrl.: 62.22 ± 6.83%; 400 nM TSA: 89.03 ±
3.51%). In addition, the percentage of cells in G2/M-
(Ctrl.: 27.19 ± 3.18%; 400 nM TSA: 7.29 ± 2,28%) and S-
Phase (Ctrl.: 9.72 ± 2.03%; 400 nM TSA: 1.14 ± 0.43%)
was significantly reduced after treatment with TSA
(Fig. 2a). Next, we analysed the effects of TSA on im-
portant G0/G1-cell cycle regulators. Interestingly, a re-
port showed that HDACi does not induce expression of
the important cell cycle regulators p21 and p27 in an
artificial lymphatic-like endothelial cell line (named
FP01) [11]. As shown in Fig. 2b and Additional file 1,
TSA induced the protein expression of p21, p27 and
Fig. 1 Effects of HDACi on primary human lymphatic endothelial cells. a, b Cells were exposed to increasing concentrations of trichostatin A
(TSA), sodium butyrate (NaB) and valproic acid (VPA) alone and (c) in the presence or absence of 20 ng/ml VEGF-A and 100 ng/ml VEGF-C for 24
h as indicated. Cell proliferation and viability was measured using the BrdU (a, c) and Alamar blue assay (b). Average absorbance values (mean ±
SE) from 4 wells per experimental condition are displayed; data are expressed as cell proliferation and vialibity in percentage (%) with regard to
solvent controls (=100%; ethanol and H2O). Results were confirmed in four independent sets of experiments. *p < 0.05 vs Ctrl. d Quantification of
cytotoxicity. Cells were incubated with increasing concentrations of TSA for 24 h as indicated. Cytotoxicity was quantified by using the LDH assay.
Average absorbance values (mean ± SE) from quadruplicate determinations per experimental condition were calculated; data are expressed as
cytotoxicity in percentage (%). e A two-dimensional, short term in vitro Matrigel assay of LECs that were left untreated or were incubated with
400 nM TSA for 6 h on Matrigel. Results were confirmed in three independent sets of experiments
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p53 in a concentration-dependent and time-dependent
manner (Fig. 2c). Surprisingly, we observed an upregu-
lation of cyclin D1 and Cdk4 after treatment with TSA.
On the other hand, since the cells were blocked in the
G0/G1-phase, expression of cyclin A was decreased
after treatment with TSA while the expression of Cdk6
was unaffected (Fig. 2d). In summary, these results
demonstrated that HDACi-induced G0/G1-cell cycle
arrest in LECs is due to modulating of the expression
of cell cycle regulating proteins.
TSA induces apoptosis through activation of the intrinsic
pathway
We next analysed the impact of TSA on apoptosis in
LECs. Figure 3a shows that TSA induced potent apop-
tosis in LECs up to 168% compared with untreated con-
trols. It has been found that HDACi induce apoptosis in
various cell types (e.g. breast cancer cells, melanoma
cells and cervix carcinoma cells) by activating caspase-
dependent pathways and regulating different pro- and
anti-apoptotic genes [16]. Therefore, we analysed the
effects of TSA on apoptosis-related proteins in LECs. As
shown in Fig. 3b and Additional file 2, increased cleav-
age of caspases 3, 7 and 9 was observed after a 24 h
exposure to TSA. Furthermore, we could demonstrate
that the expression of anti-apoptotic proteins cIAP-1
and −2 was decreased already after 4 h treatment with
TSA (Fig. 3c). To determine whether HDACi induced
the intrinsic pathway in LECs, we analysed the release of
cytochrome c from mitochondria after treatment with
TSA (Fig. 3d). We found that TSA induced a release of
cytochrome c after a 24 h treatment, indicating that the
HDACi TSA might activate the intrinsic apoptotic path-
way in LECs. These results demonstrated that TSA in-
duces the intrinsic apoptotic pathway by cytochrome c
release, activating caspases 3, 7 and 9 and downregulat-
ing the anti-apoptotic proteins cIAP-1 and −2.
Fig. 2 TSA induces G0/G1 cell cycle arrest in LECs. a Cells were incubated with 400 nM TSA and ethanol as a control for 24 h after blocking the
S-phase of the cell-cycle by treatment with a serum depleted-medium for 24 h. Analysis of cell cycle as assessed by FACS using propidium
iodide-stained LECs. The figure shows the percentage of cells in G0/G1, S and G2/M with regard to solvent controls (Ethanol). Data displayed are
representative of eight experiments that were performed revealing comparable results. *p < 0.05 vs Ctrl. b, c and d Representative western blot
analyses of LECs that were left untreated (solvent only) or were treated with TSA in a concentration- and time-dependent manner. Cell cycle
control related proteins, like p21, p27, p53, cyclin A/D1, CDK4, CDK6 and α-Tubulin as loading control were detected by enhanced chemiluminescence.
Comparable results were obtained from three independent experiments
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TSA causes nuclear accumulation of p21
Several studies have indicated that p21 plays a critical
role in the modulation of apoptosis. It is well known that
p21 regulates cell cycle progression and apoptosis de-
pending on its subcellular distribution [17, 18]. To in-
vestigate whether TSA induced nuclear accumulation of
p21 in LECs, we analysed the subcellular distribution of
p21 after treatment with TSA by immunofluorescence
staining. In our experiments we observed that accumu-
lated p21 protein was found to be located in nuclei of
the TSA treated LECs (Fig. 4). These data suggest that
TSA may induce pro-apoptotic and anti-proliferative ef-
fects in LECs by mediating nuclear accumulation of p21.
TSA upregulate the steady state of p21 mRNA
Recent studies suggested that HDACi induced p21 ex-
pression in various cancer cell lines in a transcriptional
manner [19]. To investigate further the mechanism of
HDACi-induced p21, p27 and p53 expression in human
primary lymphatic endothelial cells, we performed RT-PCR
analysis after treatment with TSA. Our data demonstrate
increased p21 mRNA expression in a time-dependent
manner while the expression of p27 and p53 was downreg-
ulated (Fig. 5a). Several studies revealed that HDACi
strongly induce the expression of p21 in many cancer cell
lines in a transcriptional, posttranscriptional, and post-
translational manner [20, 21]. We therefore first analysed a
possible posttranscriptional and posttranslational mechan-
ism of control. To verify these assumptions, we first inves-
tigated p21 mRNA and protein stability in vehicle- and
TSA-treated LECs. In the presence of actinomycin D or cy-
cloheximide, p21 mRNA and protein stability remained
unchanged in TSA-treated cells, which argues against any
posttranscriptional or -translational mechanism of p21-
induction after HDACi-treatment (Fig. 5b, c).
TSA increases p21 gene transcription through Sp1/3
binding sites
Several studies indicated that p53 and Sp1/3 binding sites
of the p21 promoter are critical for p21 induction by
HDACi treatment [22–24]. To determine the function of
p53 and Sp1/3 transcription factors in the activation of
Fig. 3 TSA treatment induces the intrinsic apoptotic pathway in LECs. a Cells were exposed to 400 nM TSA for 24 h as indicated. For apoptosis
determination, we used a colorimetric assay that quantified histone complexed DNA fragments. Average absorbance values (mean ± SE) from 3
wells per experimental condition are displayed; data are expressed as apoptotic cells in percentage (%) with regard to solvent controls (=100%;
ethanol). *p < 0.05 vs Ctrl. b and (c) Representative western blot analyses of LECs that were left untreated (solvent only) or were treated with TSA
in a concentration- and time-dependent manner. Apoptosis related proteins, like cleaved caspases 9, 3 and 7, cIAP-1/2 and α-Tubulin as loading
control were detected by enhanced chemiluminescence. Comparable results were obtained from three independent experiments. d LECs were
left untreated (solvent only, Ethanol) or were treated with 400 nM TSA for 24 h. The release of cyctochrome c to cytosol was measured using the
cytochrome c ELISA. Mean values from four independent experiments are depicted ± SE (error bars). *p < 0.05 vs Ctrl
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Fig. 4 TSA mediates nuclear accumulation of p21 protein in LECs. Subconfluent LECs were either left untreated (solvent only) or treated with 400
nM TSA for 24 h. Cells were fixed and stained with anti-p21 antibody. Blue: Hoechst stained nuclei; red: p21 protein stained with specific antibody
and secondary antibody conjugated with Alexa Fluor 546. Comparable results were obtained from three independent experiments
Fig. 5 p21, but not p27 and p53, mRNA expression is upregulated by TSA. a Semiquantitative RT-PCR analyses for p21, p27, p53 and β-Actin as
loading control were performed on total RNA extracted from subconfluent LECs. LECs were left untreated (solvent only, ethanol), or were treated
with TSA (at 400 nM) for the indicated times. Results were confirmed in three independent sets of experiments. b LECs were incubated in the
presence or absence of TSA (400 nM) for 3 h and incubated for 0, 1, 3 and 6 h with fresh media containing actinomycin D (10 μg/ml). Then, p21
mRNA levels were quantified using quantitative PCR. Comparable results were obtained from three independent experiments. c LECs were incubated
in the presence or absence of TSA (400 nM) for 3 h and incubated for 0, 1, 3 and 6 h with fresh media containing cycloheximide (10 μg/ml).
p21 and α-tubulin protein were detected by enhanced chemiluminescence. p21 protein remaining at these time points was determined by
densitometric scanning, the results of which were normalized to amounts of α-tubulin. Comparable results were obtained from three
independent experiments
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p21 promoter activity after treatment with HDACi, we
next performed luciferase promoter assays. Luciferase
reporter constructs containing the 5`-region of the p21
promoter and a series of deletional constructs were transi-
ently transfected into solvent- and TSA-treated LECs. We
could demonstrate that TSA incubated cells have shown
4.5-folds of p21 promoter activity. Furthermore, we could
show that the p21-Δ2.1 vector, which lacks the two p53-
binding sites but contains six Sp1/3-binding sites, was
still activated after TSA-treatment. To determine which
Sp1/3-binding sites of the promoter region of the p21P
(=human full length promoter) vector are responsive to
HDACi, we tested a series of deletional constructs,
lacking important Sp-binding sites. A deletion in the
Sp1-2 binding site (Δ2.3) did not change the promoter
activity after TSA-treatment. In addition, deletion of
the Sp1-4 (SmaΔ1) and Sp3-4 (SmaΔ2) binding site
abolished completely p21 promoter activity after exposure
to HDACi (Fig. 6a). In summary, we could demonstrate
that the Sp3-4 binding site in the region −100 to −81 bp
contains the main responsive elements for transcriptional
p21 activation by HDACi-treatment in primary human
lymphatic endothelial cells. To determine which nuclear
factors bind to the Sp1/3 binding site, we performed elec-
tromobility shift assays using nuclear extracts from LECs
and biotin-labeled DNA probes. In untreated cells, a dis-
tinct complex was observed to bind (Fig. 5b, lane 3). We
could find a significant increase in DNA binding activity
in cells exposed to TSA (Fig. 6b, lane 4). A decreased
binding activity was found upon addition of Sp1 antibody
(Fig. 6b, lane 6) or an Sp3 antibody (Fig. 6b, lane 8). DNA
binding activity was almost completely abolished in the
presence of Sp1/3 antibodies (Fig. 6b, lane 10). Competi-
tion assays using an excess amount of unlabeled oligo-
nucleotide (Fig. 6b, lane 1) revealed that nuclear proteins
bind to the p21 promoter sequence in a Sp1/3-dependent
manner (Fig. 6b, lanes 6 and 8).
The pan-HDACi TSA mediates its anti-proliferative effects
on LECs through p21 dependent pathways
To examine the role of p21 and p53 on TSA-mediated
anti-proliferative effects in LECs, we performed siRNA
knockdown assays. Our data demonstrate that knockdown
of p21 effectively reversed the TSA-induced growth inhib-
ition of LECs (Fig. 7a, Additional file 3) whereas silencing
of p53 showed no effects on cell proliferation (Fig. 7b,
Additional file 3). We also analysed the effect of p53 silen-
cing on TSA-induced p21 expression in LECs. The knock-
down of p53 by siRNA in LECs did not influence the
upregulation of p21 induced by TSA (Fig. 7c, Additional
Fig. 6 TSA induces p21 promoter activity via increased Sp1/3-dependent binding to the −100/–81 bp sequence. a Analyses of 5’-deletional p21
promoter-based luciferase (Luc) constructs in LECs. Schematic representation of the respective reporter gene constructs on the right and the rela-
tive Luc activities (expressed as % basal activity of the −2325/+8 construct) in graphic format on the left. Black bars, untreated controls (Ctrl.); grey
bars, TSA-treated cells (mean ± SE of three independent duplicate assays). *p < 0.05 vs Ctrl. b Representative EMSA using nuclear extracts of un-
treated (Ethanol only) and TSA-treated (at 400 nM, 1 h) LECs. The DNA-binding activity of Sp1/3 was measured by using nuclear extracts and
biotin-labeled DNA probes with or without a competitive cold DNA probe. Supershift experiments were carried out by incubating nuclear extracts
with Sp1/3 antibodies. The formation of Sp-dependent binding complexes is indicated by arrows to the left
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file 4). In summary, we could demonstrate that p21 is
essential for TSA-mediated growth inhibition in LECs.
Furthermore, we found that p53 is dispensable for TSA-
induced p21 protein expression in LECs.
Discussion
Lymphangiogenesis is an essential step in the initiation
and progression of cancer. The presence of metastasiz-
ing tumour cells in regional lymph nodes is one of the
key predictors of poor outcome in various tumour en-
tities. It has been found that intratumoural lymphatics in
melanoma are associated with distant metastasis and
poor disease free survival [10]. Further studies have
shown that enhanced lymphatic invasion in melanoma is
associated with sentinel lymph node metastasis and is a
prognostic indicator of distant metastasis [25, 26]. Since
HDACs regulate different cell functions involving cell
survival, cell cycle progression and differentiation, they
are recognized as promising targets for cancer therapy
[3]. HDACi have recently been shown to mediate anti-
angiogenic activities in endothelial cells by various mecha-
nisms, including downregulation of pro-angiogenic factors
such as VEGFR1, VEGFR2, Neuropilin-1, Tie-2 and
HIF-1α as well as upregulation of factors which inhibit
angiogenesis, such as p53 and von Hippel-Lindau. In
addition, it has been reported that various HDACi im-
paired angiogenesis in vitro and in vivo [27–30]. These
results suggest the growing importance and the possible
applicability of HDACi for anti-angiogenic therapy. Our
data provide evidence that HDACi have distinct anti-
lymphangiogenic effects in part due to the suppression
of proliferation and tube formation of primary human
lymphatic endothelial cells. Several studies recognized
HDACi as promising agents for anti-lymphangiogenic
therapy. Yamamura et al., demonstrated that NaB
inhibited pro-lymphangiogenic factors (e.g. VEGF-C
and angiopoietin-2) in the oral cancer cell line HSC-3
[31]. Furthermore, Cheng and Hung found that SAHA,
a potent HDACi, inhibits VEGF-C expression in breast
cancer cells via Sp1-dependent transcriptional repres-
sion [32]. To date, however, little is known about the
effects of HDACi on primary human lymphatic endo-
thelial cells. There is only one study by Cheng et al.
investigating the role of HDACi on lymphangiogenesis
in an artificial immortalized lymphatic cell line, gener-
ated by transfection of the endothelial cell line
EA.hy926 with PROX-1 [11]. Immortalized endothelial
cells have been shown to exhibit differences relative to
Fig. 7 The pan-HDACi TSA mediates its anti-proliferative effects on LECs through p21 dependent pathways. a Cells were treated with siRNA
against p21, p53 (b) and control siRNA and were exposed to 400 nM TSA or solvent only (=Ethanol; 100 %) for 24 h as indicated. Cell proliferation
was measured using the BrdU assay. Average absorbance values (mean ± SE) from 3 wells per experimental condition are displayed; data are
expressed as cell proliferation in percentage (%) with regard to solvent controls (=100%; ethanol). *,**p < 0.05 vs Ctrl. c Representative Western
blot analyses of LECs that were incubated with siRNA against p53 or control siRNA and treated with TSA (at 400 nM) or solvent only (Ethanol) as
indicated for 24 h. p53, p21 and α-Tubulin protein as loading control were detected by enhanced chemiluminescence. Comparable results were
obtained from three independent experiments
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their primary cell counterparts. Recently, Boerma M
et al. demonstrated that statins differentially regulated
genes involved in cell proliferation, cell cycle regulation
and DNA replication in immortalized endothelial cells
(EA.hy926) compared to in primary human endothelial
cells, making them less suited for studies focused on
genes, which are involved in the regulation of cell pro-
liferation and apoptosis [33]. The authors of the men-
tioned manuscript demonstrated that SAHA - a potent,
reversible pan-HDACi - repressed lymphangiogenesis in
the artificial FP01 cell line mimicking lymphendothelial
cells. They found that SAHA inhibited proliferation, im-
paired sprouting, tube formation and cell cycle progres-
sion at the G0/G1 and G2/M phases. In a comparable
manner, we found that HDACi inhibited proliferation of
primary lymphatic endothelial cells, impaired tube for-
mation and induced G0/G1-arrest. In the study of
Cheng and colleagues, the expression of the important
cell cycle inhibtors p21WAF1/KIP1, p27 KIP1 and cyclin A
was not changed by SAHA treatment, whereas cyclin
D1 and B1 were increased and cyclin E was reduced. In
contrast to the study of Cheng et al., we showed an ef-
fective up-regulation of the cell cycle inhibitors
p21WAF1/KIP1, p27 KIP1 and p53 by HDACi. In addition,
we provide solid evidence that cell cycle arrest at the
G0/G1-phase was accompanied by an inhibition of cyc-
lin A and up-regulation of cyclin D1. Furthermore, our
data indicate that HDACi induce p21WAF1/KIP1 expres-
sion by transcriptional activation of the promoter via
Sp1/3 binding sites. In contrast to our study, Cheng
and colleagues focused their study on Tie-2 signaling
and observed that SAHA impaired sprouting and tube
formation of the FP01 cell line by downregulating Tie-2
via transcriptional and post-transcriptional mechanisms
[11]. In addition, we showed in our primary lymphen-
dothelial cells that HDACi induced apoptosis by acti-
vating the intrinsic apoptotic pathway. Taken together,
the in part contrary results of Cheng and colleagues
may be explained by another experimental setting using
an immortalized lymphatic endothelial cell line in contrast
to primary lymphendothelial cells which are the standard
in lymphangiogenesis research. Several studies demon-
strated that HDACi can augment the extrinsic apoptotic
pathway by upregulating of cell surface death receptors
and/or ligand expression (e.g. Fas and TRAIL) causing ac-
tivation of caspase-8 [34–36]. In addition, studies have
demonstrated that HDACi induce the intrinsic apoptotic
pathway in various cancer cell lines by disruption of the
mitochondrial membrane, causing cytochrome c release
and subsequent activation of the caspases-3, −7 and −9
[37–39]. Increasing evidence has revealed that HDACi in-
duce the mitochondrial pathway by downregulating cer-
tain anti-apoptotic proteins, such as Bcl-2, Survivin and
Bcl-xL, and upregulating pro-apoptotic proteins, such as
Bad, Bid, Bim and Bmf [40–42]. In the present study, we
demonstrate that TSA induced the intrinsic apoptotic
pathway in primary human lymphatic endothelial cells by
cytochrome c release, activating caspases-3, -7 and -9 and
causing downregulation of the anti-apoptotic proteins
cIAP-1 and −2. These results suggest that the induction of
the intrinsic apoptotic pathway by TSA may be at least
one mechanism responsible for the growth inhibition of
primary human lymphatic endothelial cells and the subse-
quent anti-lymphangiogenic properties of HDACi. We
provide solid evidence that TSA induces apoptosis in pri-
mary human lymphatic endothelial cells through activat-
ing the intrinsic apoptotic pathway. Further studies have
demonstrated that HDACi suppress cancer cell growth by
inducing cell cycle arrest at the G0/G1 and/or G2/M
phases [43–47]. Almost all HDACi have been reported to
activate the important cyclin-dependent kinase (CDK) in-
hibitor p21WAF1/KIP1. Numerous studies have provided
evidence indicating that activation of p21WAF1/KIP1 is
required for the induction of G0/G1 arrest and/or
apoptosis in several cancer models by HDACi [48, 49].
Activation of p21WAF1/KIP1 after HDACi treatment is
mainly accompanied by enhanced histone acetylation
within the p21WAF1/KIP1 promoter region and increased
binding of Sp1/3 transcription factors and/or p53 on
the promoter [19–22, 50, 51]. Furthermore, several
studies have shown that increased p21WAF1/KIP1 expres-
sion leads to repression of cyclin D and cyclin A, which
contributes to the loss of CDK 4 and 6 kinase activity
and the presence of hypophosphorylated retinoblast-
oma protein, subsequently inducing G0/G1 cell cycle
arrest [52–54]. On the other hand, there is growing evi-
dence that nuclear localized p21WAF1/KIP1 contributes
to cell cycle arrest and control of DNA replication,
whereas cytoplasmic distribution of p21WAF1/KIP1 has
been suggested to inhibit apoptosis [17]. It has been
found that cytosolic p21WAF1/KIP1 effectively blocks
procaspase-3 mediated cell death in a human liver
cancer cell line and that this interaction occurs on the
mitochondria, suggesting the pivotal role of cytoplas-
mic p21WAF1/KIP1 in inhibition of apoptosis in cancer
cell lines [55, 56]. In the study of Asada and colleagues,
it has been demonstrated that cytosolic p21WAF1/KIP1
interacts as negative regulator of apoptosis by binding
and inhibiting the pro-apoptotic kinases ASK1 and JNK
in monocytes [57]. Several studies revealed that cyto-
solic p21WAF1/KIP1 has been related to drug resistance
in various cancer cell types. Vincent et al. found that
expression of Nuclear Protein 1 (NUPR1), a transcrip-
tional regulator of p21WAF1/KIP1 expression, mediates
growth benefit and chemoresistance by causing Akt-
mediated phosphorylation, subsequent cytoplasmic
relocalization of p21WAF1/KIP1 and activation of the
anti-apoptotic Bcl-xL protein in breast cancer cells
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[58]. Furthermore, Xia et al. found that p21WAF1/KIP1
translocation into the cytoplasm via constitutively ac-
tive Akt2 transfection in ovarian cancer cells enhanced
the resistance to paclitaxel, while inhibition of
p21WAF1/KIP1 translocation into the cytoplasm via Akt2
shRNA transfection in ovarian cancer cells significantly
increased paclitaxel treatment sensitivity. Additionally,
they demonstrated that knockdown of cytoplasmic
p21WAF1/KIP1 by siRNA in Akt2 overexpressed cancer
cells notably increased paclitaxel-induced apoptosis
[59]. A further study showed that the HDACi NaB in-
duced G1-cell cycle arrest and apoptosis in breast can-
cer cells. It has been shown that cell cycle arrest and
apoptosis were accompanied with increased expression
of p21WAF1/KIP1 protein and its accumulation in cellular
nuclei. Interestingly, depletion of p21WAF1/KIP1 by anti-
sense did not modified NaB-induced cell cycle arrest,
whereas NaB-induced apoptosis was abolished in a
PCNA-dependent manner. These results demonstrated
that p21WAF1/KIP1 also possesses pro-apoptotic func-
tions independent of cell cycle regulation [60]. Several
other studies observed that nuclear accumulation of
p21WAF1/KIP1 has been associated with pro-apoptotic ef-
fects [61, 62]. Taken together the role of p21WAF1/KIP1
on apoptosis may rely on different intracellular distri-
bution. In this study, we demonstrate that TSA leads to
cell cycle inhibition at the G0/G1 phase with a marked
rise in p21WAF1/KIP1, p27KIP1 and p53 expression in hu-
man primary lymphatic endothelial cells. Furthermore,
we found that p21WAF1/KIP1 accumulated in cellular nu-
clei due to TSA treatment, which may explain in part
the growth inhibiting effects of p21WAF1/KIP1 in LECs.
In addition, we observed that cyclin A was downregu-
lated by TSA treatment, whereas CDK6 was unaffected
after HDACi treatment. Interestingly, cyclin D1 and
CDK4 were upregulated after TSA treatment, suggest-
ing that the block in the G0/G1-phase due to HDAC
inhibition was mediated by the cyclin-dependent kinase
inhibitors p21WAF1/KIP1, p27KIP1, p53 and by downregu-
lation of cyclin A. Other studies have reported a cyclin
D-independent G1 cell cycle arrest. It has been re-
ported that the HDACi NaB induces G1-arrest in colon
adenocarcinoma cells by stimulating cyclin D and
p21WAF1/CIP1 and inhibiting CDK2 expression [63]. In
addition, studies have demonstrated transient overex-
pression of cyclin D1 arrested fibroblasts and HC11
mouse mammary epithelial cells in the G1-phase [64,
65]. At the present, it is not fully clear whether cyclin
D mediates any CDK-independent mechanisms in cell
cycle arrest. It is generally accepted that p21WAF1/KIP1
gene expression is regulated by p53 binding sites
localized upstream of the coding sequence (>1.9 kb)
and a proximal promoter sequence consisting of six
Sp1 binding sites [66]. Since TSA is known to induce
p21WAF1/KIP1 through increased binding of Sp1/3 tran-
scription factors and/or p53 on the promoter [19], we
hypothesized that the p21WAF1/KIP1 promoter should be
activated by the increased binding of transcription factors.
It has been observed that TSA induces p21WAF1/KIP1
expression in a human T cell leukaemia cell line via tran-
scriptional mechanisms through the Sp1 site in its
promoter [50]. A study showed that Sp3 mediates tran-
scriptional activation of the p21WAF1/KIP1 gene promoter
in osteosarcoma cells by HDAC inhibition [67]. Consistent
with these data, we observed that TSA activates p21WAF1/
KIP1 transcription in primary human lymphatic endothelial
cells via Sp1/3 binding sites in the proximal promoter
(between −100 and −80 bp). Recent studies revealed that
HDACi induce growth arrest in several cancer cell lines in
a p53-dependent and independent way [68–70]. In our
study, we observed that depletion of p53 does not influ-
ence the expression status of p21 induced by HDACi,
indicating that TSA mediated p21WAF1/KIP1 induction is
independent of p53 status in primary human lymphatic
endothelial cells. In addition, we demonstrated that p53
knockdown by siRNA does not reverse TSA mediated
inhibition of proliferation in lymphatic endothelial cells,
whereas p21WAF1/KIP1 depletion completely reversed the
growth inhibition of lymphatic endothelial cells after TSA
treatment. In our study we demonstrated that p27KIP1
protein, like p21WAF1/KIP1, increased due to TSA-
treatment, suggesting that p27KIP1 could be also involved
in TSA-induced G1-arrest in LECs. The data support
recent results showing a possible correlation between G1-
arrest and induction of p27KIP1 in various cancer cell lines
[71]. Interestingly, p27KIP1 and p53 mRNA were downreg-
ulated after TSA-treatment, whereas protein levels in-
creased at a relatively low dose and at an early time point,
which implied that p27KIP1 and p53 protein accumulation
is possibly regulated at a post-translational level. Our ob-
servations have been confirmed by various studies that
protein modification of p27KIP1 and p53 by phosphoryl-
ation or acetylation would affect the stability of modified
proteins by modulating ubiquitination dependent prote-
asome proteolysis [72, 73]. For example, it has been found
that HDACi induced apoptosis in human hepatoma
HepG2 cells. Apoptosis was accompanied with the pres-
ence of acetylated p53 together with acetylated forms of
histones and histone acetyltransferases p300 and PCAF,
indicating that HDACi influences p53 protein stability
[74]. Uehara and colleagues demonstrated that the HDACi
vorinostat enhanced protein stability of p27KIP1 and
p21WAF1/KIP1, without concomitant induction of p27KIP1
mRNA, through negative regulation of Skp2 and Cks1 in
human breast cancer cells [75]. In the study of Chen et al.,
it has been shown that the HDACi NaB induced p27KIP1-
dependent G1-Arrest in murine fibroblasts. Interestingly,
p27KIP1 mRNA-levels of butyrate-treated fibroblasts were
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decreased; instead, the stability of the p27KIP1 protein was
found to be increased upon HDACi-treatment [76]. Since
HDACi could induce the acetylation of multiple proteins
with subsequent control of the ubiquitin-proteasome
pathway, this could be one of the additional mechanisms
to affect p27KIP1 and p53 protein degradation, thus indu-
cing p27KIP1 and p53 accumulations in LECs, which need
to be confirmed in future studies. Additionally, the exactly
function of p27KIP1 in TSA-induced growth arrest in LECs
warrants further investigation of its role as a promising
therapeutic target in controlling lymphangiogenesis in
pathological conditions.
Conclusions
In summary, our study provides strong evidence that
TSA – a potent pan-HDACi - mediates distinct anti-
lymphangiogenic activities in primary human lymphatic
endothelial cells by activating the intrinsic apoptotic
pathway and inducing cell cycle arrest. TSA-induced cell
death was associated with downregulating the anti-
apoptotic proteins cIAP-1/2. Furthermore, we observed
that cell cycle arrest is associated with modulation of the
important checkpoint control proteins p21WAF1/KIP1,
p27KIP1, p53 and cyclin A resulting in G0/G1-arrest. In-
duction of p21WAF1/KIP1 in our study was associated with
increased nuclear accumulation and transcriptional acti-
vation of the promoter via Sp1/3 binding sites. We have
also demonstrated that growth inhibition of lymphatic
endothelial cells after TSA treatment is due to p21WAF1/
KIP1 induction but independent of p53 expression status.
These findings provide strong evidence for the use of
HDACi in the treatment of malignancies associated with
increased lymphangiogenesis. In conclusion, we identi-
fied in our study new targets for TSA mediated anti-
lymphangiogenic properties in primary human lymphatic
endothelial cells, which may be important for the in vivo
constellation.
Additional files
Additional file 1: Figure S1. Effects of TSA on important cell cycle
regulators. Densitometric analysis of Western blots. TSA induced the
expression of p21, p27 and p53 in a concentration-dependent manner.
LECs that were left untreated (solvent only) or were treated with TSA in a
concentration-dependent manner for 24 h as indicated. The western blot
bands were quantified by densitometry; absorbencies of p21, p27 and p53
bands were corrected for loading differences based on the corresponding
tubulin bands. Experiments were performed at least three times, and the
results are shown as mean ± SD. *p < 0.05 vs ctrl., ns = not significant.
(JPG 28 kb)
Additional file 2: Figure S2. TSA induces apoptosis through activation
of the intrinsic pathway. TSA increased the cleavage of the caspases 3, 7
and 9. LECs that were left untreated (solvent only) or were treated with
TSA in a concentration-dependent manner for 24 h as indicated. The
western blot bands were quantified by densitometry; absorbencies of
cleaved caspase 3, 7 and 9 bands were corrected for loading differences
based on the corresponding tubulin bands. Experiments were performed
at least three times, and the results are shown as mean ± SD. *p < 0.05 vs
ctrl., ns = not significant. (JPG 31 kb)
Additional file 3: Figure S3. Effects of p21 and p53 depletion in LECs
by siRNA with and without TSA-treatment. Densitometric analysis of
Western blots. Cells were treated with siRNA against p21 (A), p53 (B) and
control siRNA and were exposed to 400 nM TSA or solvent only (=Ethanol;
100 %) for 24 h as indicated. As expected, depletion of p21 and p53 protein
could not be restored after TSA treatment. The western blot bands were
quantified by densitometry; absorbencies of p21 and p53 bands were
corrected for loading differences based on the corresponding tubulin
bands. Experiments were performed at least three times, and representative
results are shown. (JPG 35 kb)
Additional file 4: Figure S4. Depletion of p53 did not reversed TSA-
induced upregulation of p21. Densitometric analysis of Western blots.
Cells were treated with siRNA against p53 and control siRNA and were
exposed to 400 nM TSA or solvent only (=Ethanol; 100 %) for 24 h as
indicated. We found, that depletion of p53 did not affected TSA-
induced upregulation of p21 protein (Fig. 7b). The western blot bands were
quantified by densitometry; absorbencies of p21 bands were corrected for
loading differences based on the corresponding tubulin bands. Experiments
were performed at least three times, and representative results are shown.
(JPG 21 kb)
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